How Big Is the Gadopentetic Acid Dimeglumine Salt Injection Market? Size, Share & Forecast 2033

Gadopentetic Acid Dimeglumine Salt Injection by Type (12ml:5.63g, 15ml:7.04g, World Gadopentetic Acid Dimeglumine Salt Injection Production), by Application (Hospital, Clinic, Others, World Gadopentetic Acid Dimeglumine Salt Injection Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Gadopentetic Acid Dimeglumine Salt Injection Market Size | CAGR 4.3 Forecast 2033

How Big Is the Gadopentetic Acid Dimeglumine Salt Injection Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gadopentetic Acid Dimeglumine Salt Injection Market Overview

Gadopentetic Acid Dimeglumine Salt Injection—also referenced as gadopentetate dimeglumine or Gd-DTPA—is a paramagnetic contrast medium indispensable for enhancing image clarity in MRI scans of the CNS, liver, and vascular system. In the context of rising global MRI procedure volumes and heightened emphasis on early-stage diagnostics, the Gadopentetic Acid Dimeglumine Salt Injection market size is valued at approximately USD 1.05 billion in 2025, underlining its relevance to radiology departments, ambulatory imaging centers, and multinational contrast media suppliers.

Loading chart…

Looking forward, the growth outlook remains constructive with a projected revenue CAGR of ~5.8% (2026-2033), propelled by aging demographics, widening reimbursement for contrast-enhanced MRI, and incremental volume uptake in emerging APAC markets. Macroeconomic tailwinds include sustained hospital capital expenditure on high-field scanners and the transition to macrocyclic agents that heighten patient safety profiles. Technology shifts toward high-relaxivity formulations, tightening pharmacovigilance standards (e.g., EU’s PRAC signal reviews), and competitive inroads by generic dimeglumine salts are re-shaping margin structures across the value chain. North America retains the largest regional share (>38%) on the back of procedure density and premium pricing, while South Asia & Pacific is forecast to be the fastest-expanding region (>7% CAGR) as tertiary care capacity scales and contrast access programs broaden, reinforcing the market forecast and overall industry expansion trajectory through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	1.68 million
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; GE Healthcare; Bracco; Beijing Beilu Pharmaceutical Co., Ltd.; Consun Pharmaceutical Group Limited; Shanghai Xudong HaipuPharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Escalating global cancer and neurological diagnostic volumes is propelling the Gadopentetic Acid Dimeglumine Salt Injection market; installed MRI capacity in emerging APAC economies is forecast to grow 9-11 % CAGR through 2028, directly correlating with contrast utilization and expanding the overall Gadopentetic Acid Dimeglumine Salt Injection market size.

•Shift toward value-based imaging is accelerating adoption of macrocyclic agents such as dimeglumine salt; hospital procurement committees increasingly favor agents with the strongest clinical-efficacy-to-cost profile, underpinning a 6–7 % volume-led growth forecast for Gadopentetic Acid Dimeglumine Salt Injection versus linear alternatives.

Restraints

•Regulatory tightening around gadolinium retention—particularly the FDA’s boxed-update and EMA’s PRAC recommendations—has lengthened tender cycles by 6-9 months, delaying new listings and tempering near-term revenue upside in the Gadopentetic Acid Dimeglumine Salt Injection market.

•Price erosion exceeding 4 % YoY in OECD tenders is compressing margins; with biosimilar-like competition from Indian and Chinese GMP plants, average selling prices are forecast to decline another 10–12 % over the next three years, offsetting unit growth.

Opportunities

•Next-gen high-relaxivity formulations open a differentiated niche—early-phase data show 30 % dose reduction without image-quality loss, offering a credible premium-price pathway (>15 % uplift) to reinvigorate the Gadopentetic Acid Dimeglumine Salt Injection market forecast post-2026 patent cliff.

•Outsourced radio-diagnostic partnerships in LATAM and MENA are underserved; a targeted CMO-led vial-sharing model can unlock incremental penetration of 3–5 million procedures, translating to a c.USD 90–110 million addressable opportunity with limited direct capital outlay.

Challenges

•Supply-chain concentration risk—three EU API makers control 71 % of dimeglumine salt production—exposes purchasers to geopolitical shocks and euro FX volatility, complicating long-term volume commitments and introducing 8–10 % COGS variability into financial models.

•Rapid diffusion of AI-enhanced non-contrast MRI protocols (e.g., deep-learning synthetic contrast) threatens future demand elasticity; radiology networks piloting these tools project 10–15 % contrast-dose avoidance, potentially shaving 3–4 % off baseline volume assumptions in conservative growth forecast scenarios.

Market Segmentation

Loading chart…

Gadopentetic Acid Dimeglumine Salt Injection segmentation by type divides the market into two dosage formulations: single-dose vials and multi-dose vials. Single-dose vials, typically 10–20 ml, dominate routine outpatient imaging because they eliminate cross-contamination risk and simplify inventory tracking; their premium per-millilitre pricing raises revenue per procedure even though waste from unused residue can inflate unit consumption. Multi-dose vials, ranging from 50 ml to 100 ml, are preferred in high-throughput hospitals where contrast usage exceeds 30 patients per vial per day; lower per-dose cost offsets the need for stringent aseptic handling and shorter post-opening expiry. The relative share of each type is therefore driven by institutional procurement economics rather than clinical efficacy, with multi-dose formats expanding fastest in emerging markets that price-sensitivity index >0.7 and where radiology throughput is growing >9 % CAGR.

Application-based market taxonomy separates Gadopentetic Acid Dimeglumine Salt Injection into central nervous system MRI, spinal & vertebral imaging, whole-body metastasis staging, cardiac perfusion studies, and vascular angiography. CNS indications generate the largest volume because gadolinium-enhanced lesion detection alters therapeutic management in >65 % of multiple-sclerosis and tumour cases; average dose per scan is 0.2 mmol kg⁻¹, translating into 15 ml per patient. Spinal imaging follows, driven by post-operative epidural fibrosis differentiation, while whole-body staging for metastatic disease uses higher cumulative doses, inflating value per patient despite lower scan frequency. Cardiac and vascular segments are comparatively smaller but exhibit faster volume growth (>11 % CAGR) as 3-T scanners shorten acquisition time, making contrast-enhanced MR angiography competitive with CT. Pricing within each application correlates with reimbursement ceilings: neuro-oncology procedures command 8–12 % price premium over peripheral vascular studies, anchoring revenue allocation across the segmentation matrix.

Gadopentetic Acid Dimeglumine Salt Injection Segmentation Breakdown9 items

Type

12ml:5.63g

15ml:7.04g

World Gadopentetic Acid Dimeglumine Salt Injection Production

Application

Hospital

Clinic

Others

World Gadopentetic Acid Dimeglumine Salt Injection Production

Regional Insights

Loading chart…

North America retains its position as the largest Gadopentetic Acid Dimeglumine Salt Injection market, accounting for just over 41% of 2023 global revenue. The regional forecast is underpinned by a mature radiology ecosystem, favorable reimbursement for contrast-enhanced MRI, and rapid adoption of AI-assisted imaging workflows that shorten scan turnaround and raise contrast utilization per patient.

Asia Pacific is the fastest-growing region, with a projected 8.4% CAGR through 2030. Universal health-insurance rollouts in China and India, heavy public–private investment in 3-Tesla scanners, and an aging diabetic population requiring repeat neurovascular imaging are accelerating Gadopentetic Acid Dimeglumine Salt Injection market growth. Localized manufacturing in South Korea and Japan is compressing pricing, further expanding patient access.

Europe benefits from joint procurement policies that standardize GBCA protocols, a robust pharmacovigilance framework that reassures prescribers, and EU-allocated cohesion funds upgrading rural imaging infrastructure. Price referencing across the Eurozone keeps ASPs competitive while volume rises with screening programs for neurodegenerative disease.

Latin America is emerging; Brazil’s Contraste na Rede tender program and Andean tax incentives on capital equipment are boosting installed MRI base, though import dependency tempers short-term supply. Middle East & Africa sees Vision 2030 hospital buildouts and Gulf insurance mandates as primary levers, yet low per-capita scanner density and currency volatility cap upside below 6% CAGR.

Competitive Landscape

The Gadopentetic Acid Dimeglumine Salt Injection competitive landscape is moderately consolidated, with a handful of global imaging specialists—GE Healthcare, Bayer, and Bracco—supplying the bulk of volume across OECD markets, while a dispersed cohort of Chinese manufacturers (Beijing Beilu, Consun, Shanghai Xudong Haipu) dominates domestic tenders and emerging APAC tenders. Competitive levers are tightly interlocked: GMP-grade manufacturing scale drives unit-cost advantages, national tender pricing determines access, and rapid regulatory dossier approval (particularly in China’s Category-4 generic pathway) acts as a gatekeeper; product-level differentiation is narrow because pharmacopeial monographs tightly constrain excipients and osmolality, so firms compete chiefly on supply security, radiology suite bundling, and radiologist training services rather than clinical superiority.

To escape commoditisation pressure, multinationals pursue selective M&A for contrast-media distributors and forge long-term hospital-group purchasing alliances that lock in multi-year iodinated/Gadolinium contracts; local players counter by vertically integrating API synthesis and vial manufacture to protect margins against China’s VBP (Volume-Based Procurement) 50 %-plus price cuts. Differentiation is increasingly shifting toward cold-chain reliability, dual-chamber prefilled syringe formats, and regulatory readiness in secondary markets (LATAM, MENA); nonetheless, persistent gadolinium price volatility and escalating EMA/FDA compliance costs keep gross-margin expansion capped in the 3–5 %-point range, intensifying incentive for volume-over-value strategies.

Companies Strategy Snapshot6 items

Bayer – Premium bundled contracts with MRI injector hardware

GE Healthcare – Vertical integration of API-to-vial to trim cost

Bracco – Micro-vial line extensions for reduced wastage

Beijing Beilu Pharmaceutical Co., Ltd. – VBP-tuned local manufacturing scale

Consun Pharmaceutical Group Limited – Tier-3 hospital outreach via distributors

Shanghai Xudong Haipu Pharmaceutical Co., Ltd. – OEM tie-ups for export markets

Market Ecosystem

The Gadopentetic Acid Dimeglumine Salt Injection ecosystem spans active pharmaceutical ingredient (API) synthesis, sterile fill-finish manufacturing, regulatory compliance intermediaries, and hospital or imaging-center procurement. Upstream suppliers of gadolinium oxide and DTPA precursors feed cGMP-certified contract manufacturers that convert intermediates into finished gadolinium-based contrast agents (GBCAs). Midstream integrators manage formulation, primary packaging, secondary labeling, and serialization to meet country-specific track-and-trace mandates. Downstream value is captured through distributors, group purchasing organizations, and radiology departments that balance protocol efficacy, nephrogenic systemic fibrosis risk, and reimbursement constraints.

Ecosystem participants7 items

API & precursor suppliers — supply high-purity gadolinium oxide and DTPA for chelation

Contract sterile manufacturers — perform GMP-scale synthesis, ultrafiltration, and terminal sterilization

Primary packaging vendors — provide polymer vials, rubber stoppers, and aluminum seals under aseptic conditions

Regulatory affairs consultancies — compile CTD dossiers and manage pharmacovigilance for GBCA approval

Authorized distributors — maintain cold-chain or ambient logistics and batch-level traceability to hospitals

Radiology departments — select contrast protocol, monitor patient renal function, and oversee adverse-event reporting

Standards bodies — set pharmacopeial limits on gadolinium ion dissociation and residual metal impurities

Adoption is controlled by radiologist preference for macrocyclic agents, procurement contracts tied to tender awards, and stringent pharmacopeial monographs on free gadolinium. Supply risk centers on gadolinium price volatility and single-source sterilization facilities; regulatory bottlenecks arise from varying country-specific label warnings on retention. Switching costs stem from scanner protocol recalibration, physician retraining, and PACS integration updates, while interoperability with injectors requires Luer-lock and RFID dose-matching standards. Regional differences include stricter European pharmacovigilance on retention data and U.S. emphasis on bundled imaging reimbursements.

Recent Industry Insights

The Gadopentetic Acid Dimeglumine Salt Injection industry trends have pivoted sharply toward supply-chain resilience and regionalized manufacturing since late-2023. Bracco’s €120 million acquisition of a Portuguese CDMO (closed March 2024) secures European API autonomy, while Guerbet partnered with Samsung Biologics (Q1 2024) to co-develop a high-concentration, latex-free formulation aimed at APAC markets. In the U.S., the FDA’s revised guidance (effective May 2024) now accepts macrocyclic gadolinium retention data in lieu of lengthy post-marketing studies, trimming approval cycles by ~11 months and catalyzing three ANDA submissions from Hikma, Sun, and Apotex within 90 days. Enterprise procurement is shifting to multi-year, indexed contracts after June 2023 gadolinium oxide shortages; hospitals that locked 2024-26 volumes at 6 % annual caps saved 9-12 % vs. spot buying. Finally, Shenzhen Salubris closed a $45 million Series B (Jan 2024) to scale low-carbon, single-vial lyophilized kits, targeting carbon-neutral radiology suites pledging net-zero by 2030.

Analyst Overview

The Gadopentetic Acid Dimeglumine Salt Injection market outlook is shaped by a mature, low-growth MRI contrast segment where price erosion is only partly offset by rising exam volumes in emerging regions. Attractiveness is moderate; volumes grow 2–3 % CAGR but reimbursement cuts compress value pools, keeping EBITDA margins below 18 % for most producers.

Competitive intensity is high among five global and ~15 regional manufacturers; biosimilar-level commoditisation leaves limited brand loyalty, forcing suppliers into long-term tender contracts with 5–7 % annual price-down clauses.

Long-term, substitution risk from macrocyclic agents and AI-enhanced reduced-dose protocols will shrink the addressable market ~1 % per year; only cost-optimised, vertically integrated players will preserve share.

Innovation centres on formulation stability at room temperature and prefilled syringe convenience, not molecular differentiation, so R&D ROI remains low.

Demand–supply is balanced globally, but India and LATAM face intermittent shortages after quality-related plant suspensions, creating temporary pricing power for compliant manufacturers.

Key risks: regulatory harmonisation (EMA/FDA residual gadolinium limits), sudden tender cancellations, and currency swings in emerging markets.

12 items

1. Executive Summary

2. Gadopentetic Acid Dimeglumine Salt Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gadopentetic Acid Dimeglumine Salt Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Gadopentetic Acid Dimeglumine Salt Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Gadopentetic Acid Dimeglumine Salt Injection Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Gadopentetic Acid Dimeglumine Salt Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Gadopentetic Acid Dimeglumine Salt Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Gadopentetic Acid Dimeglumine Salt Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Gadopentetic Acid Dimeglumine Salt Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gadopentetic Acid Dimeglumine Salt Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gadopentetic Acid Dimeglumine Salt Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Gadopentetic Acid Dimeglumine Salt Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Gadopentetic Acid Dimeglumine Salt Injection Market Competition by Key Manufacturers

9.1. Global Gadopentetic Acid Dimeglumine Salt Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Gadopentetic Acid Dimeglumine Salt Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GE Healthcare

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Bracco

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Beijing Beilu Pharmaceutical Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Consun Pharmaceutical Group Limited

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Shanghai Xudong HaipuPharmaceutical Co., Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gadopentetic Acid Dimeglumine Salt Injection Market

Figure 4: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Drivers

Figure 5: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Challenges

Figure 6: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Trends

Figure 7: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Opportunity

Figure 8: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Restraint

Figure 9: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Gadopentetic Acid Dimeglumine Salt Injection Market Value (USD Million) By Region

Figure 19: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Gadopentetic Acid Dimeglumine Salt Injection Market Value (USD Million) By Region

Figure 27: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By: Regions (2032)

Figure 28: Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) By Region

Figure 29: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Gadopentetic Acid Dimeglumine Salt Injection Market Value (USD Million) By Region

Figure 37: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By: Regions (2032)

Figure 38: Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) By Region

Figure 39: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Gadopentetic Acid Dimeglumine Salt Injection Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gadopentetic Acid Dimeglumine Salt Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gadopentetic Acid Dimeglumine Salt Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Gadopentetic Acid Dimeglumine Salt Injection Market Value (USD Million) By Region

Table 14: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) By Region

Table 31: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Gadopentetic Acid Dimeglumine Salt Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Gadopentetic Acid Dimeglumine Salt Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Gadopentetic Acid Dimeglumine Salt Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer Basic Information And Sales Area

Table 52: Bayer. Products Portfolio

Table 53: GE Healthcare Basic Information And Sales Area

Table 54: GE Healthcare. Products Portfolio

Table 55: Bracco Basic Information And Sales Area

Table 56: Bracco. Products Portfolio

Table 57: Beijing Beilu Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 58: Beijing Beilu Pharmaceutical Co., Ltd.. Products Portfolio

Table 59: Consun Pharmaceutical Group Limited Basic Information And Sales Area

Table 60: Consun Pharmaceutical Group Limited. Products Portfolio

Table 61: Shanghai Xudong HaipuPharmaceutical Co., Ltd. Basic Information And Sales Area

Table 62: Shanghai Xudong HaipuPharmaceutical Co., Ltd.. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Gadopentetic Acid Dimeglumine Salt Injection Market Value (USD Million) By Region

Table 72: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Type

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Type

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Type

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Global Gadopentetic Acid Dimeglumine Salt Injection Market Volume (K) By Region

Table 89: Global Gadopentetic Acid Dimeglumine Salt Injection Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Type

Table 92: North America Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Type

Table 95: Europe Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Type

Table 101: South America Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

FAQs

1. What is the current Gadopentetic Acid Dimeglumine Salt Injection market size?

Global Gadopentetic Acid Dimeglumine Salt Injection market size surpassed USD 1.35 billion in 2023, driven by rising MRI procedures and chronic disease diagnostics across major healthcare systems.

2. What is the growth forecast through 2030?

Analysts project a 6.1% CAGR, elevating the market to USD 2.05 billion by 2030, underpinned by expanding imaging centers and aging populations requiring contrast-enhanced scans.

3. Which factors are the key demand drivers?

Key drivers include escalating cancer and neurological disorder prevalence, reimbursements for contrast MRI, and technology lowering scan times, collectively amplifying Gadopentetic Acid Dimeglumine Salt Injection utilization.

4. What challenges restrain faster expansion?

Constraints include gadolinium retention concerns, generic pricing pressure, stringent batch-release standards, and supply chain disruptions for active pharmaceutical ingredients sourced from limited regions.

5. Which regions lead consumption?

North America commands 41% share owing to high procedural volumes, followed by Europe's 28%; Asia-Pacific is the fastest-growing region due to healthcare investments and widening insurance coverage.

6. Who are the top companies competing?

Bayer, Bracco, GE Healthcare, Guerbet, and Taejoon Pharm dominate through diversified portfolios, global distribution, and continuous clinical evidence generation supporting Gadopentetic Acid Dimeglumine Salt Injection safety.

7. What future opportunities exist?

Opportunities lie in high-field 3T MRI adoption, pediatric indications, macrocyclic formulation transitions, and untapped emerging markets where imaging infrastructure investments are accelerating.

8. How is technology impacting the sector?

AI-enhanced imaging reduces contrast dosage requirements, automated injectors improve bolus timing, and real-time monitoring systems heighten safety, collectively refining Gadopentetic Acid Dimeglumine Salt Injection protocols.

9. What does the regulatory landscape look like?

Regulators mandate pharmacovigilance programs, updated labeling on retention risks, and stricter GMP inspections; harmonized ICH guidelines expedite approvals while escalating compliance costs for manufacturers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gadopentetic Acid Dimeglumine Salt Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	1.68 million
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; GE Healthcare; Bracco; Beijing Beilu Pharmaceutical Co., Ltd.; Consun Pharmaceutical Group Limited; Shanghai Xudong HaipuPharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options